

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/061174 A1

(51) International Patent Classification:

A61K 31/415 (2006.01) A61K 31/427 (2006.01)
A61K 31/4155 (2006.01) A61P 35/00 (2006.01)
A61K 31/426 (2006.01) A61K 31/4152 (2006.01)

(21) International Application Number:

PCT/US2021/050965

(22) International Filing Date:

17 September 2021 (17.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/079,720 17 September 2020 (17.09.2020) US
63/109,097 03 November 2020 (03.11.2020) US

(71) Applicant: **ALBERT EINSTEIN COLLEGE OF
MEDICINE** [US/US]; 1300 Morris Park Avenue, Bronx,
New York 10461 (US).

(72) Inventor: **GAVATHIOTIS, Evripidis**; 50 Pheasant Run,
Roslyn, New York 11576 (US).

(74) Agent: **WARREN STEWART, Lynn M.**; Cantor Col-
burn LLP, 20 Church St., 22nd Floor, Hartford, Connecticut
06103 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMBINATION THERAPY USING BAX ACTIVATOR AGENT




Fig. 1B

(57) Abstract: A pharmaceutical combination comprising a B-cell lymphoma 2 associated X protein (BAX) activating compound and an anti-apoptotic protein inhibiting compound is provided. The disclosure also provides a method of treating cancer in a subject by administering a B-cell lymphoma 2 associated X protein (BAX) activating compound in combination with an anti-apoptotic protein inhibiting compound, such as a BCL-XL, BCL-2, BFL-1, BCL-w, or MCL-1 inhibiting compound.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*